ISPOR Real-World Evidence Summit 2025
28-30 September
Presentation
-
Long Term Healthcare Costs and Utilization Among Patients with Non Obstructive Hypertrophic Cardiomyopathy
Mar 27, 2025, 21:39 PM -
From Research to Policy: Incorporating Patient Preferences for Colorectal Cancer Treatments Into Health Technology Assessment
Mar 27, 2025, 21:39 PM -
Healthcare Resource Utilization (HCRU) and Cost among Patients with Metastatic Melanoma Receiving Nivolumab + Relatlimab (NIVO+RELA) or Nivolumab + Ipilimumab (NIVO+IPI) in the Optum Database
Mar 27, 2025, 21:39 PM -
Requirements for Patient-Reported Outcome and Data Analytics in Health Technology Assessment in England, France and Germany, and Opportunities for Methods Harmonization across European Markets
Mar 27, 2025, 21:39 PM -
Inclusion of Health-Related Quality of Life (HRQoL) and Other Patient-Reported Outcomes (PROs) in Reimbursement Reviews From the Canadian Agency for Drugs and Technologies in Health (CADTH)
Mar 27, 2025, 21:39 PM -
Economic Burden of Recurrence among Patients with High-Risk Non-Muscle-Invasive Bladder Cancer who Received Bacillus Calmette-Guérin in the United States: A SEER-Medicare Study
Mar 27, 2025, 21:39 PM -
Treatment Patterns and Healthcare Resource Utilization of Patients Early in Schizophrenia Illness Initiating Aripiprazole Lauroxil Versus Oral Aripiprazole: A Retrospective Claims-Based Study
Mar 10, 2025, 14:00 PM -
Health Utilities Associated With Pneumococcal Diseases in Children and Adults in the United States: A Targeted Literature Review and Meta-Analysis
Mar 10, 2025, 14:00 PM -
Budget Impact Model of Enhanced Lung Cancer Screening With AI/ML Tech-Based Software as a Medical Device (SaMD) on a US Cohort and Private Payer Perspective
Mar 10, 2025, 14:00 PM -
Patient-Reported Outcomes As Important Predictors of Apremilast Persistence: A Pooled Analysis of Real-World Data
Mar 10, 2025, 14:00 PM -
The Impact of Caring for Juvenile Idiopathic Arthritis Patients on Caregivers’ Quality of Life
Mar 10, 2025, 14:00 PM -
What Non-Profit Development of Pretomanid Can Teach About Paths to Innovation and Global Access to Treatments for Diseases of Poverty?
Mar 10, 2025, 14:00 PM -
Cost Effectiveness Analysis of Lanadelumab vs C1 Inhibitor for Long-Term Prophylaxis of Hereditary Angioedema: A Brazilian Private Sector Perspective
Mar 10, 2025, 14:00 PM -
Economic Burden of HER2+ Breast Cancer and the Targeted Therapies Epidemiological & Economic Impact in Trinidad and Tobago
Mar 10, 2025, 14:00 PM -
Pathways to MBS Funding for In-Vitro Diagnostics: Timelines and Success Rates in Australia
Mar 10, 2025, 14:00 PM -
Interventions to Improve Adherence and Persistence to Oral Medication: A Targeted Literature Review
Mar 10, 2025, 14:00 PM -
Assessing Disease Severity: How HTA Bodiea Evaluate Unmet Needs and Influemce Decision-Making
Mar 10, 2025, 14:00 PM -
Cost-Utility Analysis of Sequential Therapy of iCT IRd and DRd strategy for Newly Diagnosed Multiple Myeloma Patients Who are Transplant-Ineligible in China
Mar 10, 2025, 14:00 PM -
Does the 340B Program Encourage and Reward Non-Profit Hospital Consolidation?
Mar 10, 2025, 14:00 PM -
Association Between Event-Free/Distant Relapse-Free Survival and Overall Survival in Patients With Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer
Mar 10, 2025, 14:00 PM